Raltitrexed and Paclitaxel for Gastric or Gastroesophageal Junction Adenocarcinoma

Summary

This is a single-arm clinical trial.The purpose of this study is to evaluate the efficacy and safety of Raltitrexed and Paclitaxel as second-line chemotherapy for patients with unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma .The primary endpoint of this study is objective response rate.The secondary endpoint of this study is safety,progression-free survival and overall survival.

Timeline

Start

2015-05

Primary completion

2017-09-01

Completion

2018-12-01

Drugs

Indications